East Hanover, New Jersey 07936

  • Osteoarthritis, Hip


The purpose of this study is to evaluate the efficacy, tolerability, and safety of the investigational drug, lumiracoxib as compared to celecoxib and placebo in subjects with hip osteoarthritis. Both lumiracoxib and celecoxib belong to the same class of drug (COX-2 selective nonsteroidal anti-inflammatory drugs [NSAIDs]).


Inclusion Criteria: - Diagnosis of primary hip osteoarthritis - Qualifying pain intensity in the hip joint - Requiring NSAID therapy Exclusion Criteria: - Rheumatoid arthritis or other inflammatory joint disease - Disease or disorder that may interfere with pain assessment of the hip - Open knee/hip surgery within the last year - Past history of heart attack, stroke or angina (chest pain) - Liver disorder - History of severe adverse reactions of any kind under lumiracoxib or celecoxib treatment Other protocol-defined exclusion criteria may apply.



Primary Contact:


Backup Contact:


Location Contact:

East Hanover, New Jersey 07936
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.